Portfolio Lab

Medpace Holdings, Inc.

  • Stock
  • Ticker MEDP
  • ISIN US58506Q1094
  • Nasdaq

Health care · Biotechnology · USA

$610.54 −3.70%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Medpace Holdings, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

MEDPGlobal equities (VT)

$10,000 grew to $169,878. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −42.9% in 04/2022, measured from the peak in 12/2021. It took 13 months to get back to the old peak.

1-year return
+4.2%
5-year return p.a.
+21.9%
10-year return p.a.
+32.7%
Volatility p.a.
41.8%
Largest decline
−42.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue537559603660708707707716
Operating income125114126142153142147166
EBITDA133120133149160148153172
Net income11711590111135124121137
Earnings per share3.673.673.103.864.644.284.254.84
Balance sheet
Total assets2,1011,8971,5721,7531,9752,1302,0572,303
Liabilities1,2751,3041,3991,4591,5161,5311,6231,718
Equity826594172294459598434585
Cash66944146285497653503705
Cash flow
Operating cash flow191126149246193152162217
Capital expenditure-7.6-10.0-6.1-11-4.5-6.8-24-20
Free cash flow183116142235188145138196

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +69.1%, weakest 2022 at −2.4%. 8 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
22 Oct 2026$4.84
23 Jul 2026$4.25
23 Apr 2026$4.28
10 Feb 2026$4.64
23 Oct 2025$3.86
22 Jul 2025$3.10
22 Apr 2025$3.67
11 Feb 2025$3.67
22 Oct 2024$3.01
23 Jul 2024$2.75
23 Apr 2024$3.20
13 Feb 2024$2.46

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€15bn
Market cap in trading currency
$17.1bn
Enterprise value
$16.4bn
P/E
33.9
P/S
6.02
P/B
29.20
EV/Sales
5.77
EV/EBITDA
25.8
Earnings yield
2.9%
FCF yield
3.9%

Results (last four quarters)

Revenue
$2.84bn
Gross profit
–
EBITDA
$634m
Net income
$518m
Earnings per share
$18.01
Revenue per share
$101.47
Revenue growth
+8.5%
Earnings growth
+23.7%

Profitability

Gross margin
–
Operating margin
21.4%
Net margin
18.2%
Return on equity
117.9%
Return on assets
22.5%

Balance sheet and cash flow

Cash
$705m
Cash per share
$25.22
Financial debt
–
Debt/equity %
–
Current ratio
0.83
Book value per share
$20.91
Operating cash flow
$723m
Free cash flow
$668m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
28.0m
Volume
236,648
Avg. volume 3 months
258,149
Relative volume
0.9

Price and technicals

Price
$610.54
1 day
−3.7%
52-week high
$692.68
52-week low
$393.42
Distance to 52-week high
−11.9%
Distance to 52-week low
+55.2%
Distance to 50-day line
−3.8%
Distance to 200-day line
+14.4%
RSI (14)
38
Volatility 1M
33.8%

Performance

1 week
−6.6%
1 month
−6.6%
3 months
−1.5%
6 months
+41.1%
YTD
+8.7%
1 year
+3.1%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has MEDP performed since 11/2016?

$10,000 grew to $169,878 by 20 Nov 2026, which is +32.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is MEDP?

Volatility was 41.8% per year, measured on monthly returns. The largest decline from a peak was −42.9%, with the low in 04/2022.

How does MEDP compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, MEDP returned +32.8% at 41.8%. The correlation of monthly returns was 0.41; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Medpace Holdings, Inc. (MEDP): Return and risk